Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 6Carcinoma, Renal Cell 5Brain Neoplasms 3Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Kidney Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thyroid cancer, medullary 1Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Thrombocytosis 1Skin Neoplasms 1Salivary Gland Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Osteosarcoma 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

pembrolizumab 8avelumab 6fludarabine 3Radiotherapy 3Radiation 3Cyclophosphamide 3cemiplimab 2atezolizumab 2aldesleukin 2Interleukin-2 2Interferon-beta 2ALT-803 2talimogene laherparepvec 1poly ICLC 1pentetreotide 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1durvalumab 1cabozantinib 1bempegaldesleukin 1TTI-621 1Paclitaxel 1Nivolumab 1Interferon-gamma 1Influenza Vaccines 1Immunotherapy 1High-Intensity Focused Ultrasound Ablation 1Carboxylesterase 1B7-H1 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Merkel Cell × cabozantinib × Clear all
NCT02036476 2023-05-09

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Dana-Farber Cancer Institute

Phase 2 Terminated
8 enrolled 7 charts
Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡